745-65-3CCCCC[C@H](O)/C=C/C1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OGMVPRGQOIOIIMI-ZWLIRFKBSA-NSee also: Alprostadil (annotation moved to); MR 256 (annotation moved to).
745-65-3安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
説明Prostaglandin E1 is an endogenous prostaglandin with vasodilatory, anti-platelet, and anti-hypertensive activities. It is in clinical use for the treatment of erectile dysfunction and the emergency management of infants with patent ductus arteriosus. It has also been used in the treatment of peripheral arterial occlusive disease (PAD).
使用A primary Prostaglandin; easily crystallized from purified biological extracts. Vasodilator (peripheral)
一般的な説明PGE1, Alprostadil (Prostin VR Pediatric), is a naturally occurring prostaglandin that has found particular use in maintaining a patent (opened) ductus arteriosus in infants with congenital defects that restrict pulmonary or systemic blood flow. Alprostadil must be administered intravenously continually at a rate of approximately 0.1 μg/kg/min to maintain the patency of the ductus arteriosus until corrective surgery can be performed. Up to 80% of circulating alprostadil may be metabolized in a single pass through the lungs. Because apnea has been observed in 10% to 12% of neonates with congenital heart defects, this product should be administered only when ventilatory assistance is immediately available. Other commonly observed side effects include decreased arterial blood pressure, which should be monitored during infusion; inhibited platelet aggregation, which might aggravate bleeding tendencies; and diarrhea.
読み込み中…
読み込み中…
現在のフィルター条件では反応記録がありません。
読み込み中…
化学的特性Crystalline Solid